02042nam 2200469 450 991070655310332120180705162203.0(CKB)5470000002456916(OCoLC)1013542208(EXLCZ)99547000000245691620171130d2017 ua 0engurbn|||||||||txtrdacontentcrdamediacrrdacarrierExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain hearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017Washington :U.S. Government Publishing Office,2017.1 online resource (iii, 54 pages)"Serial no. 115-33."Paper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.Includes bibliographical references.Examining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain Pharmaceutical industryCorrupt practicesUnited StatesPharmaceutical policyUnited StatesGeneric drugsDevelopmentUnited StatesPrescription pricingUnited StatesCompetitionUnited StatesConsumer protectionUnited StatesLegislative hearings.lcgftPharmaceutical industryCorrupt practicesPharmaceutical policyGeneric drugsDevelopmentPrescription pricingCompetitionConsumer protectionGPOGPOBOOK9910706553103321Examining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain3533448UNINA